Analytical chemists have developed and validated a high-performance liquid chromatography method that accurately quantifies five critical medications in human control serum by using stable, non-analyte reference standards instead of expensive, unstable compound-specific materials. Published in the Journal of Pharmaceutical Health Care and Sciences, the investigation demonstrated that relative molar sensitivity values calculated against carbamazepine and caffeine allowed precise therapeutic drug monitoring for acetaminophen, cefmetazole, cefazolin, amiodarone, and its active metabolite, N-desethylamiodarone. Across spiked control serum trials, concentration measurements derived through relative molar sensitivity agreed with conventional absolute calibration benchmarks within a relative difference of plus or minus 0.50 percent, providing an analytical framework capable of reducing operational overhead and standard storage constraints in hospital clinical laboratories.
Therapeutic drug monitoring serves as an essential clinical protocol to individualize dosing regimens for pharmaceuticals characterized by narrow therapeutic ranges, predictable dose-concentration dynamics, high interindividual pharmacokinetic variability, and significant risks of concentration-dependent adverse reactions. In clinical settings, insufficient tissue exposure leads directly to therapeutic failure, whereas excessive blood concentrations increase susceptibility to severe toxicity. Because physiological responses and toxic manifestations operate along a continuous spectrum rather than shifting abruptly at nominal therapeutic boundaries, tailoring precise patient-specific doses remains a complex necessity. Many healthcare institutions lack dedicated analytical capabilities and routinely outsource drug quantification to external commercial reference laboratories, where turnaround intervals can extend up to an entire week. These prolonged logistical delays severely impede timely therapeutic adjustments for acutely ill patients who require urgent clinical decisions.
Although modern high-performance liquid chromatography instruments have become increasingly accessible and technically streamlined for routine clinical environments, managing analyte-specific certified reference materials presents persistent logistical and financial challenges. Maintaining individual certified standards requires significant operational resources to secure authentic compounds, preserve strict storage environments involving controlled temperature, humidity, and light shielding, execute routine stability checks, and frequently replace degraded stock. Furthermore, procuring certified reference materials with verified, metrologically traceable purity values involves considerable expenditure, and many clinical targets lack comprehensive commercial standard coverage altogether. Unstable pharmaceuticals, notably beta-lactam antibiotics such as cefmetazole and cefazolin, undergo rapid degradation even when kept under standard refrigeration, complicating long-term calibration practices and imposing recurring repurchasing costs on hospital facilities.
To overcome these systemic barriers, the research team implemented a quantification strategy based on relative molar sensitivity, a dimensionless coefficient defining the exact ratio of detector response per molar unit of a target analyte relative to a designated non-analyte reference compound measured under identical chromatographic parameters. When relative molar sensitivity is empirically established under standardized system conditions, target drugs can be quantified reliably using only the stable non-analyte reference material, entirely bypassing routine preparation of authentic analyte standards. While clinical immunoassays offer rapid operational speed, they frequently suffer from cross-reactivity, fail to differentiate metabolites from parent drugs, and feature restricted analyte panels. In contrast, relative molar sensitivity liquid chromatography preserves rigorous chromatographic separation, permitting the simultaneous, interference-free quantification of multiple distinct drugs and their circulating metabolites.
Building upon earlier work that established relative molar sensitivity equations for nine pharmaceutical compounds, the researchers evaluated five clinically challenging analytes that demand rigorous concentration monitoring. Acetaminophen was examined due to its severe hepatotoxicity risk during overdose situations, which requires rapid blood level determination to guide timely administration of antidotes. Cefazolin and cefmetazole, two beta-lactam antibiotics, display substantial pharmacokinetic variability among critically ill patients, creating concurrent risks of subtherapeutic antimicrobial exposure and concentration-dependent neurotoxicity. Amiodarone and its primary active metabolite, N-desethylamiodarone, feature exceptionally prolonged and variable terminal elimination half-lives spanning weeks to months; extensive tissue accumulation means that adverse effects, serious drug interactions, and cumulative toxicities can persist long after treatment cessation, requiring meticulous therapeutic drug monitoring.
Experimental analyses were carried out using an LM1010 evaluation system equipped with an ultraviolet absorption detector, dedicated dual mobile phases, and a LaChrome LM TypeA analytical column operating under manufacturer-standardized conditions. Certified reference solutions of acetaminophen, cefazolin, and an amiodarone and N-desethylamiodarone mixture were diluted across six to ten concentration tiers to construct multi-point calibration curves, with cefmetazole purity verified by quantitative proton nuclear magnetic resonance spectroscopy using internal reference standards for absolute SI traceability. Mobile phase A consisted of an aqueous buffer and mobile phase B consisted of acetonitrile, delivered in time-programmed gradient modes. Ultraviolet detection was performed at analyte-specific absorption wavelengths: 240 nanometers for amiodarone and N-desethylamiodarone, 245 nanometers for acetaminophen, 270 nanometers for cefazolin, and 275 nanometers for cefmetazole, completing chromatographic elution runs for acetaminophen, cefmetazole, and cefazolin within eight minutes.
Relative molar sensitivity values were computed from the ratio of each analyte calibration slope to previously validated non-analyte calibration slopes established for carbamazepine at 280 nanometers and caffeine at 270 nanometers. All analyte calibration curves exhibited excellent linearity, with correlation coefficients ranging from 0.9993 to 1.0000 and slope relative standard deviations between 0.3 percent and 1.5 percent across three independent preparation sets. The measured limits of quantification were established at 1.1 micromoles per liter for acetaminophen, 1.1 micromoles per liter for cefmetazole, 1.8 micromoles per liter for cefazolin, 0.30 micromoles per liter for N-desethylamiodarone, and 0.19 micromoles per liter for amiodarone, defined as concentrations corresponding to ten times the standard deviation of repeated baseline measurements.
Biological matrix performance was evaluated using pooled human liquid control serum spiked with each analyte at clinically representative therapeutic and toxic concentration levels. Prior to chromatography, spiked serum samples underwent filtration through a 0.45-micrometer syringe filter followed by spin-column solid-phase extraction centrifuged at 2,400 times gravity at 25 degrees Celsius according to standardized manufacturer protocols. Absolute recoveries from the serum matrix were satisfactory, yielding 109.7 plus or minus 2.6 percent and 102.7 plus or minus 0.68 percent for acetaminophen at 20 and 300 micrograms per milliliter; 110.9 plus or minus 1.3 percent and 106.0 plus or minus 2.9 percent for cefmetazole at 2 and 100 micrograms per milliliter; 103.2 plus or minus 6.1 percent and 103.8 plus or minus 2.3 percent for cefazolin at 2 and 100 micrograms per milliliter; 101.7 plus or minus 6.7 percent and 100.0 plus or minus 7.1 percent for N-desethylamiodarone at 0.5 and 5 micrograms per milliliter; and 97.5 plus or minus 2.9 percent and 100.0 plus or minus 8.0 percent for amiodarone at 0.5 and 5 micrograms per milliliter.
Comparative quantitative analyses demonstrated near-identical performance between the relative molar sensitivity methodology and conventional absolute multi-point calibration. Whether using carbamazepine or caffeine as the non-analyte calibrant, the relative difference in calculated serum concentrations compared to conventional calibration remained within plus or minus 0.50 percent across all tested drugs, with replicate measurement precision exhibiting relative standard deviations below 4.6 percent. Because identical solid-phase extraction pretreatment procedures were applied equally across both analytical approaches, extraction recovery characteristics influenced both quantification pipelines under uniform conditions, confirming that relative sensitivity ratios remain stable regardless of molecular mass, polarity, or chemical classification differences ranging from small hydrophilic molecules like acetaminophen to large lipophilic structures such as amiodarone.
The successful cross-wavelength quantification confirmed that empirical relative molar sensitivity values remain stable even when analytes and reference standards are monitored at divergent optical wavelengths, eliminating the need for mathematical cross-wavelength correction factors under fixed spectrophotometric conditions. Crucially, employing carbamazepine and caffeine as non-analyte calibrants overcomes the severe chemical instability of beta-lactam standards; experimental spiked serum aliquots stored at minus 30 degrees Celsius showed that cefmetazole and cefazolin remained stable for more than 210 days without measurable degradation. By relying on highly stable, SI-traceable non-analyte reference materials, hospital laboratories can avoid the degradation risks, frequent re-procurement, and specialized storage logistics associated with delicate certified drug standards.
The authors underscored several practical and structural boundaries regarding the interpretation and deployment of these findings. First, all reported relative molar sensitivity coefficients were generated using an LM1010 evaluation system with dedicated analytical columns, pre-installed parameters, and proprietary mobile phases; consequently, these coefficients represent instrument-specific properties that cannot be transferred directly to liquid chromatography equipment from alternative manufacturers without explicit empirical re-verification. Furthermore, analytical validation was conducted using spiked control serum matrices rather than genuine clinical patient samples containing varied polypharmacy regimens and endogenous biological interferences. Although clinical experience with conventional chromatography under identical column conditions has not revealed notable interfering peaks, prospective cross-validation using authentic patient blood samples remains necessary before integrating relative molar sensitivity protocols into automated hospital testing platforms.
Subject of Research: Relative molar sensitivity HPLC quantification for therapeutic drug monitoring
Article Title: Development of a relative molar sensitivity–based HPLC method for quantifying acetaminophen, two beta-lactams, amiodarone, and its metabolite
Article References: Ohtsuki, T., Enomoto, Y., Yasuda, A., Imai, R., Seto, N., Hashimoto, M., Matsushita, M., Morikawa, S., & Matsufuji, H. (2026). Development of a relative molar sensitivity–based HPLC method for quantifying acetaminophen, two beta-lactams, amiodarone, and its metabolite. Journal of Pharmaceutical Health Care and Sciences, 12(1), Article 94. https://doi.org/10.1186/s40780-026-00615-w
Image Credits: AI Generated
DOI: 10.1186/s40780-026-00615-w
Keywords: high-performance liquid chromatography, relative molar sensitivity, therapeutic drug monitoring, carbamazepine, caffeine, acetaminophen, cefazolin, cefmetazole, amiodarone, N-desethylamiodarone, certified reference materials, solid-phase extraction, metrological traceability, clinical pharmacology, serum analysis
News Source: Ophelia Keating. (November 19, 2026). Standardized HPLC Method Quantifies Five Narrow-Index Drugs Using Stable Non-Analyte Reference Standards. Scienmag.



